MX2012000298A - Dominio de union extracelular de inhibidor alosterico de un receptor tirosina quinasa. - Google Patents
Dominio de union extracelular de inhibidor alosterico de un receptor tirosina quinasa.Info
- Publication number
- MX2012000298A MX2012000298A MX2012000298A MX2012000298A MX2012000298A MX 2012000298 A MX2012000298 A MX 2012000298A MX 2012000298 A MX2012000298 A MX 2012000298A MX 2012000298 A MX2012000298 A MX 2012000298A MX 2012000298 A MX2012000298 A MX 2012000298A
- Authority
- MX
- Mexico
- Prior art keywords
- tyrosine kinase
- binding domain
- extracellular
- allosteric inhibitor
- kinase receptor
- Prior art date
Links
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 title abstract 3
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 title abstract 3
- 229940125528 allosteric inhibitor Drugs 0.000 title abstract 3
- 108091008794 FGF receptors Proteins 0.000 abstract 2
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención se refiere a un dominio de unión extracelular para un inhibidor alostérico, de tal manera que dicho dominio de unión se derive de un receptor de tirosina quinasa de transmembrana único. Más específicamente, la invención se refiere a un dominio extracelular derivado de un receptor de factor de crecimiento de fibroblastos (FGFR). Se refiere además a la utilización de este dominio para la identificación de dominios similares en la parte extracelular de otros receptores tirosina quinasa, y a un método de selección para la identificación de un compuesto pequeño inhibidor alostérico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09290537A EP2270043A1 (en) | 2009-07-03 | 2009-07-03 | Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor |
| PCT/IB2010/053054 WO2011001413A1 (en) | 2009-07-03 | 2010-07-02 | Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012000298A true MX2012000298A (es) | 2013-05-30 |
| MX345715B MX345715B (es) | 2017-02-13 |
Family
ID=41137351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012000298A MX345715B (es) | 2009-07-03 | 2010-07-02 | Dominio de union extracelular de inhibidor alosterico de un receptor tirosina quinasa. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9234025B2 (es) |
| EP (2) | EP2270043A1 (es) |
| JP (2) | JP6255156B2 (es) |
| KR (1) | KR101828092B1 (es) |
| CN (1) | CN102596991B (es) |
| AU (1) | AU2010267590B2 (es) |
| BR (1) | BR112012000029B8 (es) |
| CA (1) | CA2766972C (es) |
| DK (1) | DK2448964T3 (es) |
| ES (1) | ES2631452T3 (es) |
| HU (1) | HUE035052T2 (es) |
| IL (1) | IL217155B (es) |
| MX (1) | MX345715B (es) |
| MY (1) | MY158993A (es) |
| RU (1) | RU2604805C2 (es) |
| SG (2) | SG177427A1 (es) |
| WO (1) | WO2011001413A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2985258A1 (fr) * | 2011-12-28 | 2013-07-05 | Sanofi Sa | Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique |
| AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
| KR102328069B1 (ko) | 2014-02-21 | 2021-11-17 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 알로스테릭 단백질의 신생 설계 |
| KR102344105B1 (ko) | 2014-08-18 | 2021-12-29 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 모노시클릭 피리딘 유도체의 염 및 이의 결정 |
| JP6503450B2 (ja) | 2015-03-25 | 2019-04-17 | 国立研究開発法人国立がん研究センター | 胆管癌治療剤 |
| SG10201913213WA (en) | 2015-12-17 | 2020-03-30 | Eisai R&D Man Co Ltd | Therapeutic agent for breast cancer |
| WO2018081534A1 (en) * | 2016-10-28 | 2018-05-03 | President And Fellows Of Harvard College | Assay for exo-site binding molecules |
| WO2018237041A1 (en) * | 2017-06-22 | 2018-12-27 | The Regents Of The University Of Michigan | SPECIFIC PEPTIDE REAGENTS OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 AND METHODS |
| US11548931B2 (en) | 2017-11-16 | 2023-01-10 | Xl-Protein Gmbh | PASylated VEGFR/PDGFR fusion proteins and their use in therapy |
| CN111712245A (zh) | 2018-03-28 | 2020-09-25 | 卫材R&D管理有限公司 | 用于肝细胞癌的治疗剂 |
| CN113651662B (zh) * | 2020-12-31 | 2023-10-27 | 复旦大学附属华山医院 | 一种靶向fgfr的新型肿瘤pet分子探针及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001085769A2 (en) * | 2000-05-11 | 2001-11-15 | Wyeth | Structure of g-protein (rgs4) and methods of identifying agonists and antagonists using same |
| US7393656B2 (en) * | 2001-07-10 | 2008-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for risk stratification |
| FR2838123B1 (fr) * | 2002-04-04 | 2005-06-10 | Sanofi Synthelabo | Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf |
| US7083933B1 (en) * | 2003-05-09 | 2006-08-01 | Prosidion Limited | Methods for identification of modulators of OSGPR116 activity |
| US20070248605A1 (en) * | 2003-12-19 | 2007-10-25 | Five Prime Therapetutics, Inc. | Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention |
| FR2865934B1 (fr) * | 2004-02-05 | 2006-05-05 | Sanofi Synthelabo | Utilisation de derives d'indolizine 1,2,3 substitues, inhibiteurs des fgfs, pour la preparation de medicaments utiles pour le traitement de maladies liees a une angiogenese pathologique choroidienne |
| CN103146649B (zh) * | 2004-06-09 | 2018-05-22 | 爱丁堡大学管理处 | 神经干细胞 |
| JP2008537961A (ja) * | 2005-04-15 | 2008-10-02 | ボード、オブ、トラスティーズ、オブ、ミシガン、ステイト、ユニバーシティ | Ｇｐｃｒモジュレーター |
| FR2896247B1 (fr) | 2006-01-13 | 2008-02-29 | Sanofi Aventis Sa | Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique |
| EP1891955A1 (en) * | 2006-07-24 | 2008-02-27 | Sanofi-Aventis | Use of 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, for the preparation of a medicament intended for the treatment of degenerative joint diseases |
-
2009
- 2009-07-03 EP EP09290537A patent/EP2270043A1/en not_active Withdrawn
-
2010
- 2010-07-02 MX MX2012000298A patent/MX345715B/es active IP Right Grant
- 2010-07-02 WO PCT/IB2010/053054 patent/WO2011001413A1/en not_active Ceased
- 2010-07-02 US US13/379,822 patent/US9234025B2/en active Active
- 2010-07-02 EP EP10734333.7A patent/EP2448964B1/en active Active
- 2010-07-02 KR KR1020127002920A patent/KR101828092B1/ko active Active
- 2010-07-02 CA CA2766972A patent/CA2766972C/en active Active
- 2010-07-02 AU AU2010267590A patent/AU2010267590B2/en active Active
- 2010-07-02 RU RU2012103542/10A patent/RU2604805C2/ru active
- 2010-07-02 CN CN201080039710.5A patent/CN102596991B/zh active Active
- 2010-07-02 SG SG2011097284A patent/SG177427A1/en unknown
- 2010-07-02 JP JP2012518145A patent/JP6255156B2/ja active Active
- 2010-07-02 DK DK10734333.7T patent/DK2448964T3/en active
- 2010-07-02 BR BR112012000029A patent/BR112012000029B8/pt active IP Right Grant
- 2010-07-02 ES ES10734333.7T patent/ES2631452T3/es active Active
- 2010-07-02 HU HUE10734333A patent/HUE035052T2/en unknown
- 2010-07-02 MY MYPI2011006390A patent/MY158993A/en unknown
- 2010-07-02 SG SG10201403778TA patent/SG10201403778TA/en unknown
-
2011
- 2011-12-22 IL IL217155A patent/IL217155B/en active IP Right Grant
-
2015
- 2015-11-30 US US14/954,301 patent/US20160193192A1/en not_active Abandoned
-
2016
- 2016-10-07 JP JP2016198682A patent/JP2017036305A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012532121A (ja) | 2012-12-13 |
| BR112012000029A2 (pt) | 2016-11-08 |
| KR101828092B1 (ko) | 2018-02-09 |
| EP2270043A1 (en) | 2011-01-05 |
| BR112012000029B8 (pt) | 2021-05-25 |
| IL217155B (en) | 2019-01-31 |
| US20120094864A1 (en) | 2012-04-19 |
| JP6255156B2 (ja) | 2017-12-27 |
| CN102596991A (zh) | 2012-07-18 |
| EP2448964B1 (en) | 2017-04-12 |
| CA2766972A1 (en) | 2011-01-06 |
| BR112012000029B1 (pt) | 2020-12-08 |
| MX345715B (es) | 2017-02-13 |
| RU2012103542A (ru) | 2013-08-10 |
| IL217155A0 (en) | 2012-02-29 |
| DK2448964T3 (en) | 2017-07-24 |
| AU2010267590B2 (en) | 2016-08-04 |
| ES2631452T3 (es) | 2017-08-31 |
| US9234025B2 (en) | 2016-01-12 |
| WO2011001413A1 (en) | 2011-01-06 |
| SG10201403778TA (en) | 2014-10-30 |
| CA2766972C (en) | 2019-03-05 |
| RU2604805C2 (ru) | 2016-12-10 |
| MY158993A (en) | 2016-11-30 |
| HUE035052T2 (en) | 2018-05-02 |
| KR20120093146A (ko) | 2012-08-22 |
| US20160193192A1 (en) | 2016-07-07 |
| AU2010267590A1 (en) | 2012-02-02 |
| EP2448964A1 (en) | 2012-05-09 |
| SG177427A1 (en) | 2012-02-28 |
| JP2017036305A (ja) | 2017-02-16 |
| CN102596991B (zh) | 2016-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY158993A (en) | Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor | |
| IL194752A0 (en) | Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk | |
| MY155621A (en) | Axl antibodies | |
| ZA201007517B (en) | Inhibitors of protein tyrosine kinase activity | |
| TN2011000673A1 (en) | Bace inhibitors | |
| AP2012006166A0 (en) | Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors. | |
| CR11776A (es) | Inhibidores de bace | |
| ZA201301679B (en) | Inhibitors of bruton's tyrosine kinase | |
| SG179085A1 (en) | Pi3 kinase inhibitors and uses thereof | |
| EA200870410A1 (ru) | Антагонисты киназы | |
| PL2121687T3 (pl) | Pochodne amin tricyklicznych jako inhibitory białkowej kinazy tyrozynowej | |
| CR20120333A (es) | Isoquinolinonas y quinazolinonas substituidas. | |
| IL196337A0 (en) | Tyrosine kinase inhibitors | |
| EP2348846A4 (en) | DISUBSTITUTED AZEPANOREXINE RECEPTOR ANTAGONISTS | |
| CL2011000295A1 (es) | Compuestos derivados de pirimidil-amino-benzamida; inhibidores de tirosin-quinasa; y su uso en el tratamiento de la hipertension pulmonar. | |
| WO2011090648A3 (en) | Inhibitors of vascular endothelial growth factor (vegf) receptors and methods of use thereof | |
| MX2009010701A (es) | Metodos para inhibir la union de endosialina a ligandos. | |
| EP2521555A4 (en) | METHOD AND COMPOSITIONS FOR INCREASING SENSITIVITY AGAINST TYROSINE KINASE INHIBITORS | |
| MX2009012474A (es) | Compuestos de quinazolina. | |
| ATE557019T1 (de) | Pyrrolidin-3-ylmethyl-amin als orexin- antagonisten | |
| EP2271346A4 (en) | MONOCYCLIC CGRP RECEPTOR ANTAGONISTS | |
| EA201170585A1 (ru) | Производные изохинолинона в качестве антагонистов nk3 | |
| DE602006011697D1 (de) | Empfänger unter Verwendung von Gleichspannungoffsetkompensation für optimalen IP2 | |
| WO2008153902A3 (en) | Urotensin ii receptor antagonists | |
| EP2419522A4 (en) | METHOD AND KITS FOR THE FORECASTING OF THERAPY RESULTS OF TYROSINE CHINESE INHIBITORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |